Cardiology
Latest News
Results from 11 AHA-funded COVID-19 studies expected within months
The AHA’s COVID-19 and Its Cardiovascular Impact Rapid Response Grant initiative awards $1.2 million in grants.
News
FDA approves dapagliflozin for low-EF heart failure
From the Journals
New angiotensin studies in COVID-19 give more reassurance
A deluge of new data does not suggest harm with ACE inhibitors and angiotensin blockers in COVID-19 rates or outcomes.
Guidelines
AHA emphasizes the need for cardio-obstetrics teams
Statement from the American Heart Association explains the need for a multidisciplinary approach to managing pregnancy in women with...
From the Journals
Multisociety roadmap eyes restarting elective cardiac cases
Conference Coverage
Diastolic dysfunction is a common risk factor for cognitive decline
Proposed mechanisms for cognitive decline in patients with systolic dysfunction include low cardiac output, embolic infarctions, and hypoxic...
From the Journals
FOURIER: Evolocumab follow-up shows no cognitive adverse effects
A cognition survey of more than 22,000 FOURIER patients showed no compromise linked to evolocumab or sharply cut LDL-C levels.
From the Journals
Hydroxychloroquine-triggered QTc-interval prolongations mount in COVID-19 patients
From the Journals
Out-of-hospital cardiac arrests soar during COVID-19 in Italy
Feature
New study of diabetes drug for COVID-19 raises eyebrows
Latest News
Yale’s COVID-19 inpatient protocol: Hydroxychloroquine plus/minus tocilizumab
Yale cardiologist offers lessons from “the haze of battle” on fighting COVID-19 with little evidence.